# US 2015/0148248 A1 · Mmp2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148248 A1
- Document ID: US20150148248A1
- Status: Published application
- Kind: A1
- Application number: 14/402,913
- Filed: 2013-05-23
- Published: 2015-05-28
- Earliest claimed: 2012-05-23
- Assignees: Universite D'Aix-Marseille; Assistance Publique - Hopitaux De Marseille
- Applicants: Universite D'Aix Marseille; Assistance Publique-Hopitaux De Marseille
- Inventors: Olivier Chinot; Emeline Tabouret
- Web page: https://patentgrep.com/patent/US20150148248A1

## CPC

- G01N 33/57585: {involving compounds identifiable in body fluids}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 2333/96494: Matrix metalloproteases, e. g. 3.4.24.7
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/7014: (Neo)vascularisation - Angiogenesis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of matrix metalloproteinase-2 (MMP2) as a predictive biomarker of response to antiangiogenic therapy and survival after antiangiogenic therapy in cancer patients, and to related methods for predicting or monitoring the response to an antiangiogenic treatment and the survival after said treatment of a cancer patient.

## Claims

### Claim 1

Use of matrix metalloproteinase-2 (MMP2) as a predictive biomarker of response to antiangiogenic therapy and survival after antiangiogenic therapy in cancer patients.

### Claim 2 (depends on 1)

The use according to claim 1, wherein said antiangiogenic therapy is with a pharmacological agent which targets the vascular endothelial growth factor (VEGF) pathway.

### Claim 3 (depends on 2)

The use according to claim 2, wherein said agent is an anti-VEGF antibody.

### Claim 4 (depends on 2)

The use according to claim 2, wherein said agent is a VEGF receptor tyrosine kinase inhibitor.

### Claim 5 (depends on 1)

The use according to claim 1, wherein said cancer is associated with VEGF overexpression.

### Claim 6 (depends on 5)

The use of claim 5, wherein said cancer is selected from the group consisting of: glioblastoma, breast, colon, lung, liver, kidney, pancreas, thyroid and ovarian cancers.

### Claim 7

A method for predicting the response to an antiangiogenic treatment and the survival after treatment of a cancer patient, which comprises the step of: measuring the level of MMP2 prior to said antiangiogenic treatment, in a biological sample from said patient, wherein a higher level of MMP2 in said sample, compared to a reference value, is indicative of a response to said antiangiogenic treatment and survival after treatment of said patient.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said biological sample is a biological fluid or biopsied tumor cells or tissue.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said biological fluid is serum, plasma or urine.

### Claim 10 (depends on 7)

The method according to claim 7, wherein said MMP2 is MMP2 protein.

### Claim 11 (depends on 7)

The method according to claim 7, wherein said MMP2 is MMP2 mRNA.

### Claim 12 (depends on 7)

The method according to claim 7, which comprises measuring the level of MMP2 protein using an immunoassay.

### Claim 13 (depends on 7)

The method according to claim 7, which comprises measuring the level of MMP2 mRNA using a nucleic acid array-based, a tissue microarray-based or a quantitative reverse transcription polymerase chain reaction assay.

### Claim 14 (depends on 7)

The method according to claim 7, which comprises, after the measuring step, a further step of sorting the cancer patient into responder or non-responder based on MMP2 level in said biological sample.

### Claim 15

A method for monitoring the response to an antiangiogenic treatment of a patient suffering from cancer, comprising: measuring the level of MMP2 in a biological sample from the patient, at two or more time points during said antiangiogenic treatment, wherein an equal or higher level of MMP2 in said sample at a later time point, compared to a reference value obtained at an earlier time point, is indicative of a prolonged response to said antiangiogenic treatment, whereas a lower level of MMP2 is indicative of a resistance to said antiangiogenic therapy.
